Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022–2023, 2023–2024, and 2024–2025 seasons
PLOS One · 16.04.2026 · 21 (4) · e0347314
DOI: 10.1371/journal.pone.0347314 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.04.2026. Verfasst von Engin Berber und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Biology, Cleveland Clinic Research, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, Georgia Research Alliance.
Abstract (Originalsprache)
Seasonal influenza vaccines are available in multiple formulations including egg-based inactivated standard-dose, cell-based inactivated, recombinant, and live-attenuated. However, vaccine effectiveness and antibody responses vary by vaccine type, recipient age, and prior influenza exposures. Both age and repeated annual vaccination can modulate immune outcomes through antigenic differences between historical and updated vaccine formulations. In this three-season (2022–2023–2024–2025) study, 1,328 participants aged 9–89 years received one of six vaccine types (Fluzone standard dose (SD) or high dose (HD), Fluad, Flucelvax, Flublok, Flumist). Collected serum samples were tested for hemagglutination inhibition (HAI) activity against vaccine strains and historical circulating strains before vaccination and day 28 post-vaccination. Seroprotection and seroconversion rates were analyzed by age group and vaccine platform. Repeated vaccination across consecutive seasons was associated with reduced HAI boosting to current vaccine strains in some participants, although vaccination broadly increased antibody titers to prior strains (back-boosting) and maintained high seroprotection rates from year to year. Participants ≥65 years had lower post-vaccination HAI titers compared to younger adults and had rapid waning of HAI titers than vaccinated younger adults, yet elderly participants with HAI titers
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infection Biology, Cleveland Clinic Research, Cleveland, Ohio, United States of America.
- Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
- Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, Florida, United States of America.
- Department of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America.
ORCID-Profile: Engin Berber, Brianna M Gamez, Ted M Ross
Förderung
- National Institutes of Health
- Georgia Research Alliance
Zitieren
APA
Berber, E., Hanley, H. B., Gamez, B. M., & Ross, T. M. (2026). Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022–2023, 2023–2024, and 2024–2025 seasons. PLOS One, 21(4), e0347314. https://doi.org/10.1371/journal.pone.0347314
Vancouver
Berber E, Hanley HB, Gamez BM, Ross TM. Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022–2023, 2023–2024, and 2024–2025 seasons. PLOS One. 2026;21(4):e0347314. doi:10.1371/journal.pone.0347314
BibTeX
@article{Berber2026,
author = {Berber, Engin and Hanley, Hannah B and Gamez, Brianna M and Ross, Ted M},
title = {Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022–2023, 2023–2024, and 2024–2025 seasons},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0347314},
doi = {10.1371/journal.pone.0347314}
}
EUVIMED